Reduction or loss of gap junction activity is associated with various human cancers, including ESCC [127,128]; however, the mechanism of action in ESCC remains unknown, and there are only a limited number of studies related to Cx26 and Cx43 [129]. This evidence concerns the gene GJB2 and cancer.